All the news Showing 10 of 163 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Deaths of Japanese patients prompt label change for simeprevir HCP Live / 24 November 2014 CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe AbbVie press release / 21 November 2014 Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis Liz Highleyman / 11 November 2014 A 12-week all-oral regimen of daclatasvir, asunaprevir and beclabuvir, with or without ribavirin, cured 86 to 90% of genotype 1 hepatitis C patients with cirrhosis in the phase 3 UNITY-2 trial, while the ... Merck’s four-week treatment for hepatitis C misses the mark Wall Street Journal / 11 November 2014 Olysio (simeprevir) approved for use in combination with sofosbuvir Johnson & Johnson press release / 07 November 2014 Unique 'pay if you clear' proposal for new hepatitis drug BBC / 15 October 2014 NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C NICE / 25 September 2014 AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials HIVandHepatitis.com / 15 September 2014 AbbVie 3D regimen cures most genotype 1 HCV in people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An oral regimen of three direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people with both HIV and genotype 1 hepatitis C co-infection ... Interferon-free hepatitis C treatment works for people on methadone or buprenorphine Liz Highleyman / 28 July 2014 People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a ... ← Prev12345...17Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive